AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03307239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cold application
Description: We manufactured two ice packs (17 × 12 cm) with a combined weight of 600 g. The ice packs were inserted into adjustable wraps made in our hospital so that they can be fixed next to the skin on each side of the chest tube in patients awaiting CTR. The combined contact area of the ice packs was approximately 25 cm in diameter around the chest tube.~For patients of the experimental group, they were received 15-minutes cold application.
Study NCT03307239 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: tap water packs application
Description: We manufactured two tap water packs (17 × 12 cm) with a combined weight of 600 g. The tap water packs were inserted into adjustable wraps made in our hospital so that they can be fixed next to the skin on each side of the chest tube in patients awaiting CTR. The combined contact area of the tap water packs was approximately 25 cm in diameter around the chest tube.~For patients of the sham group, they were received 15-minutes tap water application.
Study NCT04452968 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intermittent fasting
Description: Women were required to fast for 16 hours and consume their allotted calories during the remaining 8 hours.
Study NCT04452968 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caloric restriction
Description: Daily caloric requirement was calculated using basal metabolic rate (BMR) calculator. All women were directed to decrease calorie intake by 500 calories.
Study NCT04452968 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric restriction
Description: Daily caloric requirement was calculated using basal metabolic rate (BMR) calculator. All women were directed to decrease calorie intake by 500 calories.
Study NCT00999544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant 40mg
Description: Aprepitant 40mg, p.o. pretreatment
Study NCT00999544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant 200mg
Description: Aprepitant 200mg, p.o. pretreatment
Study NCT00999544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone 0mg, p.o.
Description: Oxycodone 0mg, p.o.
Study NCT00999544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone 20mg, p.o.
Description: Oxycodone 20mg, p.o.
Study NCT00999544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone 40mg, p.o.
Description: Oxycodone 40mg, p.o.
Study NCT00999544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone 0mg, IN
Description: Oxycodone 0mg, IN
Study NCT00999544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone 15mg, IN
Description: Oxycodone 15mg, IN
Study NCT00999544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone 30mg, IN
Description: Oxycodone 30mg, IN
Study NCT01310465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: zoledronic acid, 5mg(100ml), intravenous, one time at three days postoperatively
Study NCT01310465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride
Description: sodium chloride, 100ml, intravenous, one time at three days postoperatively
Study NCT01555372 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hook Plate
Description: All participants will have an open reduction internal fixation. The affected upper limb will be temporarily fixed by a sling after admission. Under necessary test, general anaesthetic and antibiotic prophylaxis, the patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with HP. X-ray was applied to check the grade of reduction before the operation is completed. Post-operative care will include early active mobilization managed by a standard physiotherapy rehabilitation regime.
Study NCT01555372 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Locking Plate
Description: All participants will have an open reduction internal fixation. The affected upper limb will be temporarily fixed by a sling after admission. Under necessary test, general anaesthetic and antibiotic prophylaxis, the patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with locking plate. X-ray was applied to check the grade of reduction before the operation is completed. Post-operative care will include early active mobilization managed by a standard physiotherapy rehabilitation regime.
Study NCT02222610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Study NCT02222610 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted Retinal Photocoagulation (TRP)
Description: TRP to areas of retinal ischemia
Study NCT01735266 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Air colonoscopy
Description: Colonoscopy will be performed with conventional air insufflation during colonoscope insertion.
Study NCT01735266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water exchange colonoscopy
Description: Water exchange method (The air pump was turned off before colonoscopy. During colonoscope insertion, residual air in lumen was suctioned and 37°C water was infused into lumen to obtain lumen visualization) was used in whole or left colon. Air was insufflated until cecum was reached or appendix opening was seen.
Study NCT04085549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Berry Oil Cream
Description: Cream containing berry and plant oils and humectants; a medical device product in development
Study NCT04085549 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reference Cream
Description: Commercial refence cream not containing berry and plant oils.
Study NCT04310111 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-RFA
Description: Use EUS-RFA to treat unresectable pancreatic cancer
Study NCT01072188 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arginine/Calcium Carbonate
Description: One time treatment
Study NCT01072188 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nupro - Fluoride Free
Description: Brush twice daily
Study NCT01400698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saizen® A
Description: Continuous or intermittent treatment with recombinant human Growth Hormone (r-hGH) 0.067 milligram/kilogram/day (mg/kg/day) subcutaneously (sc).
Study NCT01400698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saizen® B
Description: Observed until the first signs of puberty and then continuous treatment with r-hGH 0.067 mg/kg/day sc or observed without treatment.
Study NCT01400698 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observation only
Description: Subjects were only observed.
Study NCT00487357 — intervention group
Intervention type: BEHAVIORAL
Intervention: Supplemental Survey
Description: Questionnaire give during home visit to collect behavioral, risk factors and other smoking status data on MATCh parents/guardians.
Study NCT02851641 — intervention group
Intervention type: PROCEDURE
Intervention: pushed mono-canaliculonasal intubation
Study NCT03260257 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Neurofeedback (NFB) will be administered to improve gamma band response. NFBs effects will be measured on gamma coherence and working memory.
Study NCT00660543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gadolinium
Description: Given IV
Study NCT03481335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHAP-P Sessions
Description: Residents of intervention communities (barangays) aged 40+ are openly invited to attend CHAP-P sessions. At CHAP-P sessions, trained local volunteers (Barangay Health Workers, or BHWs) collect consent, measure blood pressure, collect other physical measurements, and conduct a survey to determine clients' risk of diabetes. Based on the findings, BHWs provide education and/or referrals. CHAP-P sessions are held twice a month, and clients are encouraged to continuing attending for ongoing follow-up and monitoring.
Study NCT00660543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol Non-Stoichiometric Magnetite
Description: Given IV
Study NCT00660543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DCE MRI
Study NCT00660543 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DCE MRI
Study NCT02807623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: The participants will take their first dose of the study drug immediately after influenza vaccine receipt. The medication will be blinded and dispensed by a research pharmacist. The participants will receive instructions on the dosing, frequency and a recommendation to take with food or milk and will be provided a snack with their first dose.
Study NCT02807623 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compound Exercise of Push-ups
Description: The participants will perform an exercise intervention of push-ups as immediately as possible but no more than 15 minutes after influenza vaccine receipt. The number of pushups performed will be at least 80% of the participants last Army Physical Fitness Test (APFT) score in one session. The number of pushups will be recorded. A baseline lactate fingerstick blood specimen will be collected with either the serology sample (if possible) or from the hand opposite the vaccine receipt arm prior to performing pushups and a second finger stick sample within 3-8 minutes, but no more than 15 minutes after vaccine receipt.
Study NCT02807623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral placebo
Description: The participants will take their first dose of the study drug immediately after influenza vaccine receipt. The medication will be blinded and dispensed by a research pharmacist. The participants will receive instructions on the dosing, frequency and a recommendation to take with food or milk and will be provided a snack with their first dose.
Study NCT04081922 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: Using ultrasound, place the needle in the erector spinae fascia plane at T7-8 level. Then, 0.25% ropivacaine 0.5 ml is injected to confirm the needle location. After checking the location, 0.25% ropivacaine 0.5 ml/kg is administered. This procedure is repeated at contralateral side.
Study NCT03190395 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPVI Group
Description: CPVI Group:The ablation strategy of Circumferential pulmonary vein isolation (CPVI)will be operated on 60 patients with paroxysmal atrial fibrillation.
Study NCT03190395 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPVI+LARA Group
Description: CPVI+LARA Group: The ablation strategy of Circumferential pulmonary vein isolation combine with Left atrium roofline ablation(CPVI+LARA) will be operated on 60 patients with paroxysmal atrial fibrillation.
Study NCT03840863 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Commercially-Available Energy Drink
Description: Participant will consume 2 cans of an energy drink (16 oz./can) per day. One in the morning and one in the afternoon.
Study NCT02498301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin will be provided to subjects either daily with placebo, or twice daily depending on which of the two experimental arms they are randomized to
Study NCT00660543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DSC MRI
Study NCT02498301 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered twice daily or once daily with rifaximin depending on which experimental arm they are randomized to
Study NCT02498301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered twice daily or once daily with rifaximin depending on which experimental arm they are randomized to
Study NCT00908453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosphenytoin
Description: 15mg/kg, 18mg/kg or 22.5mg/kg of loading doses of fosphenytoin
Study NCT00660543 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DSC MRI
Study NCT00660543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diffusion Weighted Imaging
Description: Undergo DWI
Study NCT05229484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: an integrated multimodal lifestyle intervention (MLifeI)
Description: The MLifeI program focused on the roles of health responsibility, review of lipid profile, complications of imbalanced lipid profile, lipid management and nutritional education.
Study NCT00930891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Chemotherapy (PCDE or PE)
Description: PCDE: cisPlatin 75 mg/m² D2 ; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 4 cycles~PE: cisPlatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 4 cycles
Study NCT00930891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Treatment (PCDE or PE + bevacizumab)
Description: PCDE: cisPlatin 75 mg/m² D2; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 4 cycles Bevacizumab 7.5 mg/kg, D1, until progression~PE: cisPlatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 4 cycles Bevacizumab 7.5 mg/kg, D1, until progression
Study NCT00930891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prerandomization Chemotherapy (PCDE or PE)
Description: PCDE: cisPlatin 75 mg/m² D2; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 2 cycles~PE: cisplatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 2 cycles
Study NCT00930891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prerandomization Chemotherapy (PCDE or PE)
Description: PCDE: cisPlatin 75 mg/m² D2; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 2 cycles~PE: cisplatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 2 cycles
Study NCT02933788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Cilostazol sustained release capsule is new drugs developed by Otsuka Korea. This drugs have platelet aggregation inhibiting action, peripheral vasodilating action and endothelial function improving action.
Study NCT00660543 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diffusion Weighted Imaging
Description: Undergo DWI
Study NCT00660543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI-Based Angiogram
Description: Undergo TOF MR angiography
Study NCT02933788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Description: Aspirin may prevent coronary thrombosis in patients with cardiovascular event risk factors, such as ischemic heart disease family history, hypertension, diabetes mellitus, dyslipidemia and obesity.
Study NCT01775644 — intervention group
Intervention type: DRUG
Intervention: Bevacizumab
Description: Administration of treatment will be as used in normal daily routine under local labeling.
Study NCT02219646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil
Description: Vardenafil 10 mg twice daily for six months
Study NCT02219646 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo two tablets daily for 6 months
Study NCT02752880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH1 group
Description: Participants were randomly assigned 1:1 to receive either YH1 or placebo for 12 consecutive weeks.
Study NCT02752880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo group
Description: Participants were randomly assigned 1:1 to receive either YH1 or placebo for 12 consecutive weeks.
Study NCT00515151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% Octenidine with 30% 1-propanol and 45% 2-propanol
Description: Before insertion of the catheter, the entry site was disinfected with the assigned solution over an area of >200 cm² for at least one minute. The assigned solution was then applied for care of the entry site during the change of dressings, usually every 2 to 3 days.
Study NCT00515151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 74% Ethanol with 10% 2-propanol
Description: Before insertion of the catheter, the entry site was disinfected with the assigned solution over an area of >200 cm² for at least one minute. The assigned solution was then applied for care of the entry site during the change of dressings, usually every 2 to 3 days.
Study NCT00660543 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI-Based Angiogram
Description: Undergo TOF MR angiography
Study NCT01680484 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bitter chocolate
Study NCT01680484 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Orange juice
Study NCT02253901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BILR 355 BS
Study NCT02253901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 BS
Study NCT02253901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Study NCT01248195 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Amisulpride open label
Description: 4-week open label amisulpride treatment
Study NCT02253901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study NCT01248195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6-week amisulpride double blind treatment
Description: 6-week amisulpride double blind treatment
Study NCT02253901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRUVADA
Study NCT01198756 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent seasonal influenza vaccine GSK2282512A
Description: For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 17 years of age, single intramuscular dose.
Study NCT01198756 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix™ VB
Description: For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects of 9 to 17 years of age, single intramuscular dose.
Study NCT01198756 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix™ YB
Description: For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects of 9 to 17 years of age, single intramuscular dose
Study NCT01248195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6-week olanzapine double blind treatment
Description: 6-week olanzapine double blind treatment
Study NCT01248195 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 12-week clozapine open-label treatment
Description: 12-week clozapine open-label treatment
Study NCT01248195 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Description: Psychosocial intervention
Study NCT00506350 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose
Description: A single dose of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.
Study NCT01198756 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent seasonal influenza vaccine GSK2282512A
Description: Single intramuscular dose for primed subjects, two doses for unprimed subjects.
Study NCT01127893 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab
Description: Tanezumab 10 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
Study NCT00506350 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses
Description: Two doses of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and Day 21.
Study NCT01127893 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab
Description: Tanezumab 5 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
Study NCT01127893 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab
Description: Tanezumab 2.5 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
Study NCT04154436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate (NaHCO3) Plus Solution
Description: Alkaline Solution
Study NCT03723616 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will view 24 ads with and without health warnings. Additionally, 16 control non-tobacco ads matched for graphical content, presence of text, people, and other factors will be randomly distributed among these ads.